On May 21, 2020, Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, announced it has raised $76 million in an oversubscribed Series B offering that closed on May 18, placing the company's total funding in excess of $100 million. Wilson Sonsini Goodrich & Rosati represented Nautilus in the transaction.

The funding round was led by Vulcan Capital, the multi-billion-dollar investment arm of Vulcan Inc., the company founded by Microsoft co-founder and philanthropist Paul G. Allen. In addition to Vulcan, Perceptive Advisors, Bezos Expeditions (the VC arm of Amazon founder Jeff Bezos), and Defy Partners were new investors in the Series B offering. Previous investors AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group also participated in the round.

The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine. The capital will be used to accelerate development of Nautilus’ proprietary proteomics platform and the expansion of scientific and engineering staff across a variety of levels and disciplines.

The Wilson Sonsini team that advised Nautilus on corporate and IP matters in the transaction includes Rob Kornegay, Zach Myers, Ryan Greecher, Ben Capps, and Vern Norviel.

For more information, please see Nautilus' press release.